Hormonal
Pharmacotherapy using GLP-1 receptor agonists (semaglutide) or dual GIP/GLP-1 agonists (tirzepatide) produces significant weight loss (10-20%) and improves obesity-related comorbidities, serving as a necessary adjunct to lifestyle intervention for patients with BMI ≥30 kg/m2 or ≥27 kg/m2 with complications.
If you have a BMI over 30 (or over 27 with health issues like high blood pressure or diabetes), lifestyle changes alone often aren't enough because your body fights weight loss. Medications like semaglutide or tirzepatide, taken once weekly, can help you lose 10-20% of your body weight and improve your health conditions. These are long-term treatments; stopping them usually leads to regaining the weight. If cost is a barrier, ask your doctor about starting at a lower dose, which may still be effective.
Pharmacotherapy is indicated as an adjunct for those living with obesity (body mass index [BMI] ≥30 kg/m2) or those who are overweight (BMI ≥27 kg/m2) with a least one weight-related complication... Weight loss of 5–15% has been shown to improve and/or prevent progression of obesity-related comorbidities.
Why this rating
Based on multiple Phase 3 RCTs (STEP 1, SURMOUNT-1) cited in the text.
Source
Pharmacotherapy for the management of overweight and obesity?
Patrice M. Forner et al. · Australian Journal of General Practice · 2025
DOI 10.31128/ajgp-09-24-7411
More from this paper
- Discontinuation of obesity pharmacotherapy leads to significant weight regain and recurrence of metabolic benefits loss, necessitating lifelong treatment or intensive lifestyle support.Strong
- Phentermine/topiramate and naltrexone/bupropion are effective alternative pharmacotherapies for weight loss (4-10%) in patients without cardiovascular contraindications, offering oral administration options.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →